How CJC-1295 Is Different From Other Peptides Longer Half Life for Better Results One major difference is its long half life
Aescin has demonstrated evidence of its clinically noteworthy efficacy in the therapy of thyroid cancer 34 , liver dysfunction 35 , hyperlipidemia 36 , diabetes 37 , cardiac vein insufficiency, post-operative edema 38 , cardiac damage 39 , brain trauma 40 , and neurobehavioral disorders 41
Theyre probably already in that shake, says Israetel
For instance, in the BRIDGE trial comparing DMF alone to a compound containing DMF plus other FAE, while both were significantly more effective than a placebo, there was no significant difference between them, indicating that DMF is the active ingredient in terms of efficacy
However, such platforms are not capable of robustly producing glycoproteins, which represent the majority of biologics approved or in development